review · American Journal of Cardiovascular Drugs

Safety and Efficacy of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors After Acute Coronary Syndrome: A Meta-analysis of Randomized Controlled Trials

Ahmed Atia
Mohamed Elmallahy
Maya Magdy Abdelwahab
Heba Aboeldahab
Amr Elrosasy
Ahmed Wageeh
Menna M. Aboelkhier
M. Elneny
Bashaer Elawfi
Somaya Sayed
Ahmed Abdelaziz

202411 citationsOpen accessSuez Canal University

Abstract

PCSK9i was associated with better lipid profile and quality of life of patients and can be recommended as an optimal treatment strategy. Further trials should study combinations of PCSK9i with other lipid-lowering drugs.

Research topics

Lipoproteins and Cardiovascular Health
Pharmaceutical Economics and Policy
Coronary Interventions and Diagnostics

Sustainable Development Goals

3Good Health and Well-being

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1007/s40256-023-00621-5

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.